Publicación Oficial de la Sociedad Ecuatoriana de Neurología, de la Liga Ecuatoriana Contra la Epilepsia y de la Sociedad Iberoamericana de Enfermedad Cerebrovascular

Toxina botulínica

 

Uso de Toxina Botulínica Tipo A en Pacientes con Espasmo Hemifacial en Cuba. Botulinum Toxin A In Hemifacial Spasm In Cuba.

Objective: To evaluate botulinum toxin A therapy in patients with hemifacial spasm attended in a Neurology Service in Cuba. Patients and methods: 35 patients with hemifacial spasm were treated with botulinum toxin A during 15 months. Some parameters of botulinum toxin were collected including doses, latency, maximum duration and total duration of improvement. Clinical data were determined, such as functional status, gravity, frequency and adverse events. Results: There was a high percentage of female with hemifacial spasm. Most patients showed a latency of 48 hs, maximum duration until 60 days and total duration of improvement of 3 months. Functional status decreased through time, independently of hemifacial spasm onset and its origin. Parameters related to functional status, as gravity and frequency also diminished significantly their categories. Botulinum toxin doses were statistically increased over this treatment, independently of any patient conditions. Only eight patients showed adverse events (facial muscle weakness and ptosis). Conclusions: Recovery of functional status, and low rate of adverse events observed during botulinum toxin treatment might suggest that this therapy seems to be effective and low-risk under our conditions.

Leer artículo completo

Tratamiento del Blefaroespasmo y Síndrome de Meige con toxina botulínica. Experiencia y seguimiento en 18 casos.

Treatment with botulinum toxin (BT) is a good therapeutic alternative for patients with blepharospasm and Meige’s syndrome. We report follow up results of 18 patients with blepharospasm and Meige’s syndrome treated with botulinum toxin, to asses therapy response. 67 injection sessions were performed with a mean dose of 40.2 ± 26.5 UI. The duration of effect was 120 ± 50 days and the global assessment of the results on a scale from 0 to 4 (0 no results to 4 very good results) was an average of 3.1 ± 0.72. We can say that botulinum toxin therapy was good or very good in 14 (77.7%) patients with blepharospasm and Meige’s Syndrome. Only 3 cases (16.6%) had significative complications, reversible in all cases.

Leer artículo completo

Indicaciones y manejo de la toxina botulínica

Botulinus toxin (BTX) is the most potent biological toxin yet known. It is produced by Clostridium botulinium, a Gram positive bacteria. Type A Botulinus toxin is the most widely used in human drug trials. It has become the treatment of choice for blepharospasm, hemifacial spasm, cervical dystonia and laryngeal dystonia. It may also be used in the treatment of patients with oromandibular dystonia and limb dystonia, specially writer’s cramp, and has been used successfully in the treatment of spasticity and cerebral paralysis. There are many benefits from this treatment, including improved walking, improved posture of wheelchair patients, improvement of patients with spasms and easier extension of their arms and knees. The toxin also alleviates pain and may be used in therapeutic trials for prediction of the response to surgical elongation.

Leer artículo completo

 
 
Licencia Creative Commons
Salvo que se estipule lo contrario el contenido de la Revista Ecuatoriana de Neurología está bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivadas 4.0 Internacional.